Last reviewed · How we verify

The Egyptian IVF-ET Center — Portfolio Competitive Intelligence Brief

The Egyptian IVF-ET Center pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Clomiphene citrate / hCG Clomiphene citrate / hCG marketed Ovulation induction agent / Gonadotropin-releasing hormone analog combination Estrogen receptor (clomiphene); LH receptor (hCG) Reproductive Medicine / Fertility
Metformin / clomid / hCG Metformin / clomid / hCG marketed Combination fertility agent (insulin sensitizer + ovulation inducer + gonadotropin) Reproductive Medicine / Fertility

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for The Egyptian IVF-ET Center:

Cite this brief

Drug Landscape (2026). The Egyptian IVF-ET Center — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/the-egyptian-ivf-et-center. Accessed 2026-05-16.

Related